482 results on '"Prinjha, Rab K"'
Search Results
2. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
3. Endogenous bioluminescent reporters reveal a sustained increase in utrophin gene expression upon EZH2 and ERK1/2 inhibition
4. Drug-induced loss of imprinting revealed using bioluminescent reporters of Cdkn1c
5. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer
6. Bromodomain factor 5 is an essential regulator of transcription in Leishmania
7. Cohesin couples transcriptional bursting probabilities of inducible enhancers and promoters
8. Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140
9. Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention
10. Influenza virus infection causes global RNAPII termination defects
11. Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism
12. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
13. Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro
14. Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia
15. Epigenetic Regulation of T Cell Memory: Recalling Therapeutic Implications
16. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe
17. Brd4 bridges the transcriptional regulators, Aire and P-TEFb, to promote elongation of peripheral-tissue antigen transcripts in thymic stromal cells
18. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells.
19. Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors
20. Combined noncanonical NF-[kappa]B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
21. Remodeling of the Enhancer Landscape during Macrophage Activation Is Coupled to Enhancer Transcription
22. Click chemistry enables preclinical evaluation of targeted epigenetic therapies
23. The Epigenetic Reader Protein SP140 Regulates Dendritic Cell Activation, Maturation and Tolerogenic Potential
24. Selective inhibition of BET proteins reduces pancreatic damage and systemic inflammation in bile acid- and fatty acid ethyl ester- but not caerulein-induced acute pancreatitis
25. Anti-inflammatory Effects of BET Protein Inhibition Through Modulation of Gene Transcription
26. Supplementary Methods; Supplementary Figures S1-S6; and Supplementary Tables S1-S4 from Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL
27. Data from Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL
28. List of Contributors
29. The Epigenetics of Autoimmunity and Epigenetic Drug Discovery
30. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
31. IL-10 Drives Glycolysis and Hinders Mitochondrial Pathways in Human Macrophages: Implications for Inflammatory Bowel Disease and Anti-TNF Treatment
32. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
33. BET Inhibition Improves NASH and Liver Fibrosis
34. Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432
35. Epigenetic and transcriptional plasticity of myeloid cells in Cystic Fibrosis
36. Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation
37. N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
38. A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
39. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
40. Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia
41. Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis
42. Selective inhibition of CD4⁺ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors
43. Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
44. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses
45. Additional file 16 of Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140
46. Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate
47. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts
48. Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease
49. Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression
50. Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.